Abstract
Background. Patient eligibility for renal replacement therapy (RRT) modalities is frequently debated, but little prospective data are available from large patient cohorts. Methods. We prospectively evaluated medical and psychosocial eligibility for the three RRT modalities in patients with chronic kidney disease (CKD) stages III-V who were enrolled in an ongoing prospective cohort study conducted at seven North American nephrology practices. Results. Ninety-eight percent of patients were considered medically eligible for haemodialysis (HD), 87% of patients were assessed as medically eligible for peritoneal dialysis (PD) and 54% of patients were judged medically eligible for transplant. Age was the leading cause of non-eligibility for both PD and transplant. Anatomical concerns (adhesions, hernias) were the second most frequent concern for PD eligibility followed by weight. Weight was also a concern for transplant eligibility. The proportion of patients medically eligible for RRT did not vary by CKD stage. There was, however, significant inter-centre variation in the proportion of patients medically eligible for PD and transplant. Ninety-five percent of patients were considered psychosocially eligible for HD, 83% of patients were assessed as psychosocially eligible for PD and 71% of patients were judged psychosocially eligible for transplant. The percentage of patients who were assessed as having neither medical nor psychosocial contraindications for RRT was 95% for HD, 78% for PD and 53% for transplant. Conclusions. Most CKD patients are considered by their medical care providers to be suitable for PD. Enhanced patient education, promotion of home dialysis for suitable patients and empowerment of patient choice are expected to augment growth of home dialysis modalities.
Original language | English |
---|---|
Pages (from-to) | 555-561 |
Number of pages | 7 |
Journal | Nephrology Dialysis Transplantation |
Volume | 24 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2009 |
Bibliographical note
Funding Information:Acknowledgements. CRIOS was supported by grants from Baxter Healthcare Corporation to the participating centres. The following individuals participated in the study at the respective centres: Brigham and Women’s Hospital, Boston, MA: Ajay Singh MD, Bharati Mittal MD; Metabolism Associates, New Haven, CT: Fred Finkelstein MD; Mid-Atlantic Nephrology Associates, Baltimore, MD: Jeff Posner MD; Nephrology Associates, Birmingham, AL: John Brouillette MD, Jeff Glaze MD, Jason Tsai MD, David Tharpe MD; Humber River Regional Hospital, Toronto, ON: David Mendelssohn MD; Royal Victoria Hospital, Montreal, QU: Tomoko Takano MD, Paul Barre MD; and Queen Elizabeth Health Science Centre, Halifax, NS: Steven Soroka MD.
Funding Information:
Conflict of interest statement. CRIOS was supported by grants from Baxter Healthcare Corporation to the participating centers. Three of the authors are, or were, employees of Baxter. No restrictions were placed upon the other coauthors in term of study design, analysis of the data and/or the drafting of the manuscript. Baxter did not provide any of the non-Baxter coauthors with honoraria or any other personal financial compensation or support.
ASJC Scopus Subject Areas
- Nephrology
- Transplantation